BioModelsapplication/xmlhttps://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000946?filename=curation_notes.txthttps://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000946?filename=Evans2005-biopax3.owlhttps://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000946?filename=Evans2005-biopax2.owlhttps://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000946?filename=manifest.xmlhttps://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000946?filename=Evans2005.xmlhttps://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000946?filename=metadata.rdfhttps://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000946?filename=Evans2005.cpshttps://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000946?filename=figure2_abc_pH7.pnghttps://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000946?filename=Evans2005-octave.mhttps://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000946?filename=Evans2005-matlab.mhttps://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000946?filename=curation_image.pnghttps://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000946?filename=Evans2005.sedmlhttps://www.ebi.ac.uk/biomodels/model/download/BIOMD0000000946?filename=Evans2005.odeprimary200OKMatthew RobertsManually curatedordinary differential equation modelL2V4https://www.ebi.ac.uk/biomodels/BIOMD0000000946falseBioModelsSBMLModelsEvans2005 Compartmental model for antineoplastic drug topotecan in breast cancer cells2005MODEL1805210001Neil D. Evans, Rachel J. Errington, Michael J. Chapman, Paul J. Smith, Michael J. Chappell, Keith R. GodfreyNeil D. Evans10.1002/acs.856, A compartmental model for the in vitro uptake kinetics of the anti-cancer agent topotecan is proposed. This model provides a description of the activity of the drug, and subsequent delivery of active form to the nuclear DNA target. The unknown model parameters are estimated from two-photon laser-scanning microscopy data, which provide concentrations of topotecan (active plus inactive forms) in the extracellular region containing live human breast tumour cells (MCF-7 cell line), the cytoplasm and the nucleus. This determines an output structure for which the model is uniquely identifiable, that is, the unknown parameters are uniquely determined from noise-free, continuous and perfect data. The model allows in silico predictions of the dose dependence of target binding. Copyright 2005 John Wiley & Sons, Ltd.. null, 19. School of Engineering, University of Warwick, Coventry CV4 7AL, U.K. Department of Medical Biochemistry, University of Wales College of Medicine, Cardiff CF14 4XN, U.K. School of MIS-Mathematics, Coventry University, Coventry CV1 5FB, U.K. Department of Pathology, University of Wales College of Medicine, Cardiff CF14 4XN, U.Kmroberts@ebi.ac.uk10.1002/acs.856EMBL-EBIBIOMD0000000946In this paper a compartmental modelling approach is applied to provide a mathematical description of the activity of the anti-cancer agent topotecan, and delivery to its nuclear DNA target following administration. The activity of topotecan in defined buffers is first modelled using a linear two compartment model that then forms the basis of a cell based model for drug activity in live cell experiments. An identifiability analysis is performed before parameter estimation to ensure that the model output (i.e., continuous, perfect and noise-free data) uniquely determines the parameters. Parameter estimation is performed using experimental data which offers concentrations of active and inactive forms of topotecan from high performance liquid chromatography methods.A mathematical model for the in vitro kinetics of the anti-cancer agent topotecan.Evans Neil D ND, Errington Rachel J RJ, Shelley Michael M, Feeney Graham P GP, Chapman Michael J MJ, Godfrey Keith R KR, Smith Paul J PJ, Chappell Michael J MJfalseEvans2005 - Compartmental model for antineoplastic drug topotecan in breast cancer cells Compartment model for the antineoplastic drug topotecan. Modelling drug in its active lactone and inactive hydroxy acid forms in the medium, extracellular, cytoplasm and nucleus. 2024-08-222024-09-022018-05-21BIOMD0000000946SBO:0000587SBO:0000338SBO:0000189SBO:000046815094319CHEBI:63632CHEBI:70727CHEBI:25000CHEBI:35610CHEBI:35868CHEBI:16991OBI:0001285MODEL1805210001BIOMD0000000946PW:0002367PATO:0002355GO:0005634GO:0005576GO:0005737GO:0065004GO:0015562GO:0005488C111589606BTO:0000093BTO:0000316EFO:000042810.1002/acs.856